Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Suzhou Basecare Medical's Enterprise Value is HK$267.2 Mil.
Suzhou Basecare Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-278.2 Mil. Therefore, Suzhou Basecare Medical's EV-to-FCF for today is -0.96.
The historical rank and industry rank for Suzhou Basecare Medical's EV-to-FCF or its related term are showing as below:
HKSE:02170'
s EV-to-FCF Range Over the Past 10 Years
Min: -100.97 Med: -0.07 Max: 3.81
Current: -0.96
During the past 8 years, the highest EV-to-FCF of Suzhou Basecare Medical was 3.81. The lowest was -100.97. And the median was -0.07.
HKSE:02170's EV-to-FCF is ranked worse than 100% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 23.86
vs HKSE:02170: -0.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Suzhou Basecare Medical (HKSE:02170) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Suzhou Basecare Medical's PE Ratio (TTM) for today is calculated as:
Suzhou Basecare Medical's share price for today is HK$1.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Suzhou Basecare Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.879.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Suzhou Basecare Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Basecare Medical EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Suzhou Basecare Medical's EV-to-FCF falls into.
Suzhou Basecare Medical's current Enterprise Value is HK$267.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Suzhou Basecare Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-278.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Basecare Medical (HKSE:02170) has a EV-to-FCF of -0.96 as of Aug. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Suzhou Basecare Medical and its competitors. According to the industry distribution chart, Suzhou Basecare Medical ranks #999999 out of 413 companies in the Medical Devices & Instruments industry.
Is Suzhou Basecare Medical's EV-to-FCF too high?
Suzhou Basecare Medical's current EV-to-FCF is -0.96. Based on the distribution chart, Suzhou Basecare Medical ranks #999999 out of 413 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Suzhou Basecare Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #999999 out of 413 companies for EV-to-FCF. This places Suzhou Basecare Medical in the lower half of its industry. The industry median EV-to-FCF is 23.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.86, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current EV-to-FCF is -0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.93, compared to a current price of HK$1.40 — trading 52.2% below its estimated fair value. The current EV-to-FCF is -0.96. Suzhou Basecare Medical's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current EV-to-FCF is -0.96 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued.
The current stock price of HK$1.40 is trading 52.2% below its estimated GF Value™ of HK$2.93.
GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.
Key valuation signals for HKSE:02170:
EV-to-FCF: -0.96
GF Value™: HK$2.93 vs. price of HK$1.40 (52.2% below fair value)
No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
70GF Score
Get the complete analysis for HKSE:02170
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02170 has been successfully added to your 
